Thursday , December 14 2017
Home / Letter From The Editor / Editor’s Note, SGLT2-I Issue #5

Editor’s Note, SGLT2-I Issue #5

We’ve been bringing you these special newsletters about the SGLT2 inhibitors and hopefully they are helping you see how these new medications can be part of your patient treatment plan. For this edition, we have gone to some of the patients on the only SGLT2 Inhibitor currently available, Invokana. In addition, we have updated the insurance coverage list for this medication, and if you’d like to share how this class of drugs work with your colleagues we have a set of Homerun Slides, SGLT-2 Inhibitors: A New Modality for Treating Type 2 Diabetes, you can use.